A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase not reported
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 66
- Population
- FEMALE · 30 Years to 65 Years
- Duration
- 2023-10-16 to 2024-10-28
- Intervention
- 367 mg Pomanox group; 700 mg Pomanox group; Control group
- Comparator
- Control group
- Outcomes measured
- Change in skin melanin index. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin wrinkles. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin hydratation. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin elasticity. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin erythema index. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin pores. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin acne. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in skin keratin. — At day 1 (visit V1), day 29 (visit 2) and day 85 (visit 3).; Change in Human Procollagen I N-Terminal Propeptide blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in Human Procollagen I C-Terminal Propeptide blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in Metalloproteinase-1 blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in hyaluronic acid blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in superoxide dismutase activity blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in reduced gluthathione blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in pentosidine blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in carboxymethyl-lysine blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in interleukin-1 alpha blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in interleukin-6 blood levels. — At day 1 (visit V1) and day 85 (visit 3).; Change in stool microbiota composition. — At day 1 (visit V1) and day 85 (visit 3).; Change in skin microbiota composition. — At day 1 (visit V1) and day 85 (visit 3).
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Skin ageing · 100%Title contains controlled term: skin ageing. Abstract contains controlled term: skin ageing, photoaging. Source terminology contains: skin ageing. Title supplies longevity context: ageing. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.